HRP20211942T1 - Medicinska uporaba 5'-adenozin difosfat riboze (adpr) - Google Patents

Medicinska uporaba 5'-adenozin difosfat riboze (adpr) Download PDF

Info

Publication number
HRP20211942T1
HRP20211942T1 HRP20211942TT HRP20211942T HRP20211942T1 HR P20211942 T1 HRP20211942 T1 HR P20211942T1 HR P20211942T T HRP20211942T T HR P20211942TT HR P20211942 T HRP20211942 T HR P20211942T HR P20211942 T1 HRP20211942 T1 HR P20211942T1
Authority
HR
Croatia
Prior art keywords
adpr
patient
adenosine diphosphate
use according
diphosphate ribose
Prior art date
Application number
HRP20211942TT
Other languages
English (en)
Croatian (hr)
Inventor
Robert Shalwitz
Original Assignee
Invirsa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invirsa, Inc. filed Critical Invirsa, Inc.
Publication of HRP20211942T1 publication Critical patent/HRP20211942T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
HRP20211942TT 2016-02-18 2017-02-17 Medicinska uporaba 5'-adenozin difosfat riboze (adpr) HRP20211942T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662296665P 2016-02-18 2016-02-18
US201662428721P 2016-12-01 2016-12-01
EP17708104.9A EP3416654B1 (en) 2016-02-18 2017-02-17 Medical use of 5'-adenosine diphosphate ribose (adpr)
PCT/US2017/018253 WO2017143113A1 (en) 2016-02-18 2017-02-17 Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Publications (1)

Publication Number Publication Date
HRP20211942T1 true HRP20211942T1 (hr) 2022-03-18

Family

ID=58191671

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211942TT HRP20211942T1 (hr) 2016-02-18 2017-02-17 Medicinska uporaba 5'-adenozin difosfat riboze (adpr)

Country Status (16)

Country Link
US (3) US11110112B2 (cg-RX-API-DMAC7.html)
EP (2) EP3978003A1 (cg-RX-API-DMAC7.html)
JP (4) JP6946353B2 (cg-RX-API-DMAC7.html)
KR (2) KR102622656B1 (cg-RX-API-DMAC7.html)
CN (2) CN117482102A (cg-RX-API-DMAC7.html)
AU (2) AU2017219878B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018016398A2 (cg-RX-API-DMAC7.html)
DK (1) DK3416654T3 (cg-RX-API-DMAC7.html)
ES (1) ES2900524T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211942T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057052T2 (cg-RX-API-DMAC7.html)
IL (2) IL291574B2 (cg-RX-API-DMAC7.html)
LT (1) LT3416654T (cg-RX-API-DMAC7.html)
PL (1) PL3416654T3 (cg-RX-API-DMAC7.html)
PT (1) PT3416654T (cg-RX-API-DMAC7.html)
WO (1) WO2017143113A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057052T2 (hu) 2016-02-18 2022-04-28 Invirsa Inc 5'-adenozin-difoszfát-ribóz (ADPR) gyógyászati alkalmazása
WO2019191026A2 (en) * 2018-03-27 2019-10-03 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)
KR102789553B1 (ko) * 2021-09-07 2025-04-03 주식회사 펄스인마이어스 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용
WO2024181817A1 (ko) * 2023-03-02 2024-09-06 주식회사 펄스인마이어스 암의 예방 또는 치료를 위한 adp-리보오스 결합 펩티드 및 adp-리보오스의 병용 요법
WO2026073064A1 (en) * 2024-09-30 2026-04-02 Invirsa, Inc. 5'-adenosine diphosphate ribose (adpr) for use in improving visual acuity

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0618214A1 (en) 1993-04-01 1994-10-05 Merrell Dow Pharmaceuticals Inc. Unsaturated phosphonate derivatives of purines and pyrimidines
JPH07247210A (ja) 1994-03-09 1995-09-26 Sunstar Inc 口腔用組成物
CA2302687A1 (en) * 1997-09-11 1999-03-18 Oxigene, Inc. Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
KR20010114214A (ko) 1999-02-26 2001-12-31 인스파이어 파마슈티컬스 인코퍼레이티드 우리딘, 아데닌 및 시티딘 디포스페이트 및 그의 유사체에의한 점막수화 촉진방법
CN1370238A (zh) 1999-06-16 2002-09-18 艾科斯有限公司 人聚(adp-核酸)聚合酶2的物质和方法
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US20050009777A1 (en) 2001-07-25 2005-01-13 Mack Stephen Robert Non-natural carbon-linked nucleotides and dinucleotides
US20030236217A1 (en) 2002-05-21 2003-12-25 Shalwitz Robert A. Treatment of mucositis
US20070212395A1 (en) 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US20050276762A1 (en) * 2004-06-15 2005-12-15 Tapas Das Topical compositions containing 5'-adenosine-diphosphate ribose
CA2609549A1 (en) 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
JP5221368B2 (ja) 2005-11-14 2013-06-26 サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク(セエヌエールエス) Parp活性のインヒビター及びその使用
WO2008154129A1 (en) 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
US20110217262A1 (en) 2010-03-05 2011-09-08 Kornfield Julia A Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
WO2011141909A2 (en) 2010-05-10 2011-11-17 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
MX360666B (es) 2011-05-12 2018-11-13 Foresight Biotherapeutics Inc Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides.
US20160287622A1 (en) 2013-11-18 2016-10-06 Massachusetts Institute Of Technology Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction
HUE057052T2 (hu) 2016-02-18 2022-04-28 Invirsa Inc 5'-adenozin-difoszfát-ribóz (ADPR) gyógyászati alkalmazása
WO2019191026A2 (en) 2018-03-27 2019-10-03 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)

Also Published As

Publication number Publication date
BR112018016398A2 (pt) 2018-12-18
HUE057052T2 (hu) 2022-04-28
KR20230148389A (ko) 2023-10-24
AU2017219878A1 (en) 2018-08-09
JP2019505596A (ja) 2019-02-28
US20220054522A1 (en) 2022-02-24
AU2017219878B2 (en) 2022-12-22
US12370209B2 (en) 2025-07-29
IL291574B2 (en) 2025-05-01
JP2025032189A (ja) 2025-03-11
IL291574A (en) 2022-05-01
ES2900524T3 (es) 2022-03-17
US20200330498A1 (en) 2020-10-22
US11110112B2 (en) 2021-09-07
EP3416654B1 (en) 2021-10-27
PT3416654T (pt) 2021-12-22
WO2017143113A1 (en) 2017-08-24
CA3014071A1 (en) 2017-08-24
JP2021193126A (ja) 2021-12-23
KR20180111841A (ko) 2018-10-11
IL261095B (en) 2022-04-01
EP3416654A1 (en) 2018-12-26
CN117482102A (zh) 2024-02-02
EP3978003A1 (en) 2022-04-06
DK3416654T3 (da) 2021-12-13
JP7222042B2 (ja) 2023-02-14
CN108601793B (zh) 2024-08-23
JP6946353B2 (ja) 2021-10-06
LT3416654T (lt) 2022-01-10
IL261095A (en) 2018-10-31
KR102883682B1 (ko) 2025-11-10
US11857561B2 (en) 2024-01-02
PL3416654T3 (pl) 2022-03-21
JP7600282B2 (ja) 2024-12-16
KR102622656B1 (ko) 2024-01-10
CN108601793A (zh) 2018-09-28
AU2023201678A1 (en) 2023-04-13
JP2023055858A (ja) 2023-04-18
AU2023201678B2 (en) 2025-03-13
US20240091249A1 (en) 2024-03-21
IL291574B1 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
JP2021519315A5 (cg-RX-API-DMAC7.html)
JP6392241B2 (ja) 3,5−ジアミノ−6−クロロ−n−(n−(4−フェニルブチル)カルバムイミドイル)ピラジン−2−カルボキサミド化合物
ES2553788T3 (es) 3,5-diamino-6-cloro-N-(N-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazino-2-carboxamida
JP2021098728A5 (cg-RX-API-DMAC7.html)
ES2802175T3 (es) Tieno [3,2-d]pirimidinas, furo[3,2,d]pirimidinas y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones del virus sincitial respiratorio
JP2018199697A (ja) 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体
JP2023071933A5 (cg-RX-API-DMAC7.html)
ES2717898T3 (es) Efecto potenciador para agentes antitumorales
JP2014518268A5 (cg-RX-API-DMAC7.html)
JP2019505596A5 (cg-RX-API-DMAC7.html)
ES2949441T3 (es) Métodos para el uso de 5'-adenosina difosfato ribosa (ADPR)
JP2010502738A (ja) ナトリウムチャネル遮断剤および浸透圧調節物質での処置により粘膜水和および粘膜クリアランスを増強する方法
JP6392243B2 (ja) アリールアルキル及びアリールオキシアルキル置換の上皮ナトリウムチャネル遮断化合物
JP2021502358A5 (cg-RX-API-DMAC7.html)
JP2001131075A (ja) 抗hiv剤
ES2945865T3 (es) Combinación de un derivado de 6-oxo-1,6-dihidropiridazina que tiene actividad anticancerígena con un derivado de quinazolina
JP2022169780A5 (cg-RX-API-DMAC7.html)
US11883423B2 (en) Nucleobase analogue derivatives and their applications
CN104507918A (zh) 用于治疗或预防肺炎病毒感染和相关疾病的组合物和方法
HRP20210040T1 (hr) (2r,4r)-5-(5′-klor-2’-fluorbifenil-4-il)-2-hidroksi-4-[(5-metiloksazol-2-karbonil)amino]pentanska kiselina
US20180162869A1 (en) Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
JP6553726B2 (ja) 腫瘍治療剤